Dogwood Therapeutics, Inc. (DWTX)

NCM – Цена в реальном времени. Валюта: USD

1.65

+0.17 (11.49%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

1.52

-0.13 (-7.88%)

После закрытия: Jun 26, 2026, 7:46 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Dogwood Therapeutics, Inc. (DWTX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Dogwood Therapeutics, Inc. (DWTX)

Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M

Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Видео

No Data

Пресс-релизы

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M

Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

Search stocks

Dogwood Therapeutics, Inc. (DWTX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Dogwood Therapeutics, Inc. (DWTX)

Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M

Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Видео

No Data

Пресс-релизы

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M

Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy